Editas Medicine reports Q4 EPS (55c), consensus (33c)

Reports Q4 revenue $30.6M, consensus $37.17M.”Our objective and strategy to become a leader in in vivo gene editing accelerated in the fourth quarter after we achieved in vivo preclinical proof of concept ahead of schedule and shared positive preclinical in vivo data demonstrating the potential of our platform technology to achieve gene upregulation, or amplifying the expression of an existing protein to achieve clinically relevant levels that could potentially drive cures across tissues with a single dose,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine (EDIT). “We believe the ability to provide in vivo gene editing via gene upregulation holds the potential to significantly expand the addressable therapeutic possibilities for CRISPR-based gene editing, and we are poised to make meaningful progress towards the clinic in 2025.” “The data we have shared over the last several months demonstrate our ability to attain in vivo gene editing via gene upregulation to increase the level of a functioning protein to address diseases caused by loss of function or deleterious mutations. Notably, our progress highlights the potential of our gene upregulation strategy across multiple tissues with our ‘plug ‘n play’ program,” said Linda C. Burkly, Ph.D., Chief Scientific Officer, Editas Medicine. “I am proud of our team’s progress, underscoring the therapeutic promise of our scientific work as a significant step towards the clinic as we develop our pipeline of potentially transformative in vivo gene editing medicines.”